Hypertension Monitoring in Glioma Patients Treated With Bevacizumab

Conditions

• Glioma Patients

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Bevacizumab — DRUG
  Patients with histological diagnosis of anaplastic astrocytoma (WHO Grad III) or Glioma (WHO Grad IV) assigned to bevacizumab treatment (monotherapy or adjunctive to chemotherapy) for therapeutic reasons

Study Details

Prospective casecontrol study in glioma patients undergoing treatment with bevacizumab (Avastin). At present there are no data on the correlation between occurrence of arterial hypertension and clinical outcome in patients with glioma or anaplastic astrocytoma. We will investigate whether glioma patients developing hypertension under bevacizumab treatment have a better outcome in terms of progression free survival, response rate and overall survival than equally treated patients remaining normotensive. Moreover, we will describe the dynamics of change in blood pressure after administration of bevacizumab in those patients developing hypertension. * Trial with medicinal product

Key Dates

First listed

Jan 11, 2010

Start date

Jan 31, 2010

Status verified

Jun 2013

Primary completion

Aug 31, 2012

Completion

Aug 31, 2012

Study Design

Enrollment

40 participants (actual)

Arms

• Arm: Glioma Patient receiving Bevacizumab
  Patients with histological diagnosis of anaplastic astrocytoma (WHO Grad III) or Glioma (WHO Grad IV)assigned to bevacizumab treatment (monotherapy or adjunctive to chemotherapy) for therapeutic reasons

Primary Outcome Measure

Incidence of Hypertension [ Time Frame: Hypertension under treatment ]